Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavyret in HCV-negative Recipients of HCV-positive Liver Transplants
NCT03208127Phase 4Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- Nov 2017
- Primary completion
- Jun 2021
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of glecaprevir + pibrentasvir in hepatitis C (HCV), sponsored by Massachusetts General Hospital. Primary endpoint: Sustained Virological Response at 12 weeks post treatment. Started Nov 2017; status: terminated.
02
Drugs
glecaprevir + pibrentasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03208127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03208127.